Home Cart Sign in  
Chemical Structure| 1354690-24-6 Chemical Structure| 1354690-24-6

Structure of Leniolisib
CAS No.: 1354690-24-6

Chemical Structure| 1354690-24-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Leniolisib is a potent and selective PI3Kδ inhibitor currently in used for the treatment of immunodeficiency disorders.

Synonyms: CDZ173

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Leniolisib

CAS No. :1354690-24-6
Formula : C21H25F3N6O2
M.W : 450.46
SMILES Code : CCC(N1C[C@@H](NC2=C(CN(C3=CC(C(F)(F)F)=C(OC)N=C3)CC4)C4=NC=N2)CC1)=O
Synonyms :
CDZ173
MDL No. :MFCD30470232
InChI Key :MWKYMZXCGYXLPL-ZDUSSCGKSA-N
Pubchem ID :57495353

Safety of Leniolisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Leniolisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:2.23 μM

  • p110β

    PI3Kβ, IC50:0.424 μM

  • p110α

    PI3Kα, IC50:0.244 μM

  • p110δ

    PI3Kδ, IC50:0.011 μM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05438407 APDS PHASE3 ACTIVE_NOT_RECRUITING 2025-12-30 University of California Los A... More >>ngeles, Los Angeles, California, 90095, United States|Stanford University, Standford, California, 94305-5366, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States|National Institutes of Health, Bethesda, Maryland, 20814, United States|Necker Hospital Paris, Paris, 75015, France|Kyoto University Hospital, Kyoto, 606-8507, Japan|Institute of Science Tokyo Hospital, Tokyo, 113-8519, Japan Less <<
NCT02859727 Activated PI3Kdelta Syndrome (... More >>APDS); PASLI Disease Less << PHASE2|PHASE3 ACTIVE_NOT_RECRUITING 2027-01-21 Pharming Investigative Site, B... More >>ethesda, Maryland, 20892, United States|Pharming Investigative Site, Minsk, 223053, Belarus|Pharming Investigative Site, Prague 5, CZE, 15006, Czechia|Pharming Investigative Site, Dresden, 01307, Germany|Pharming Investigative Site, Brescia, BS, 25123, Italy|Pharming Investigative Site, Palermo, PA, 90127, Italy|Pharming Investigative Site, Rotterdam, 3000 CA, Netherlands|Pharming Investigative Site, Moscow, 117198, Russian Federation Less <<
NCT06249997 APDS Gene Mutation PHASE3 RECRUITING 2025-03-31 Tokyo Medical And Dental Unive... More >>rsity Hospital, Tokyo, Bunkyo-ku, 113-8510, Japan|Hiroshima University Hospital, Hiroshima, Hiroshima City, 734-8551, Japan Less <<
NCT06549114 Primary Immunodeficiency Disor... More >>ders (PIDs) Less << PHASE2 RECRUITING 2025-10-25 National Institute of Health, ... More >>Bethesda, Maryland, 20892, United States Less <<
NCT05693129 APDS PHASE3 RECRUITING 2026-02-28 University of California Los A... More >>ngeles, Los Angeles, California, 90095, United States|National Institutes of Health, Bethesda, Maryland, 20814, United States|The University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Rainbow Childrens Hospital, Shaker Heights, Ohio, 44122, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Kyoto University Hospital, Kyoto, 606-8507, Japan|Institute of Science Tokyo Hospital, Tokyo, 113-8519, Japan|Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAúDE DE COIMBRA, Coimbra, 3000-075, Portugal|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Great Ormond Street Hospital, London, WC1N3JH, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.10mL

2.22mL

1.11mL

22.20mL

4.44mL

2.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories